337 related articles for article (PubMed ID: 8862006)
1. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs.
Izquierdo MA; Scheffer GL; Flens MJ; Shoemaker RH; Rome LH; Scheper RJ
Cytotechnology; 1996; 19(3):191-7. PubMed ID: 8862006
[TBL] [Abstract][Full Text] [Related]
2. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
4. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
[TBL] [Abstract][Full Text] [Related]
5. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.
Izquierdo MA; Scheffer GL; Flens MJ; Giaccone G; Broxterman HJ; Meijer CJ; van der Valk P; Scheper RJ
Am J Pathol; 1996 Mar; 148(3):877-87. PubMed ID: 8774142
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
7. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Laurençot CM; Scheffer GL; Scheper RJ; Shoemaker RH
Int J Cancer; 1997 Sep; 72(6):1021-6. PubMed ID: 9378536
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
12. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of multidrug resistance involve proteins: a flow cytometric analysis.
Boutonnat J; Bonnefoix T; Mousseau M; Seigneurin D; Ronot X
Anticancer Res; 1998; 18(4C):2993-9. PubMed ID: 9713498
[TBL] [Abstract][Full Text] [Related]
16. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
17. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Borst P; Kool M; Evers R
Semin Cancer Biol; 1997 Jun; 8(3):205-13. PubMed ID: 9441949
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
19. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein U; Walther W; Lemm M; Naundorf H; Fichtner I
Int J Cancer; 1997 Sep; 72(5):885-91. PubMed ID: 9311609
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
